Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
about
Tacrolimus versus cyclosporine A for prevention of graft versus host disease after stem cell transplantationDefining the intensity of conditioning regimens: working definitionsTacrolimus versus cyclosporine A for prevention of graft versus host disease after stem cell transplantationCurrent and emerging strategies for the prevention of graft-versus-host diseaseMilestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current DevelopmentsHaematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution.Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trialHeparanase promotes engraftment and prevents graft versus host disease in stem cell transplantationCurrent and future approaches for control of graft-versus-host disease.Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimensGenetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donorsNon-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experiencePretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.Current issues in chronic graft-versus-host disease.High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantationPredictors of health-related quality of life in patients treated with auto- and allo-SCT for hematological malignancies.A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation.Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndromeNovel regulatory therapies for prevention of Graft-versus-host disease.Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15.Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcomeExpansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease.Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host diseaseChoosing between stem cell therapy and drugs in myelofibrosis.Curcumin attenuates acute graft-versus-host disease severity via in vivo regulations on Th1, Th17 and regulatory T cellsImpact of donor age on outcome after allogeneic hematopoietic cell transplantation.Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantationHigh-dose cyclophosphamide for graft-versus-host disease prevention.A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamideSclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of diseaseAllogeneic immune replacement as cancer immunotherapy.Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationMyeloablative conditioning regimens for AML allografts: 30 years later.Emerging therapies for graft-versus-host disease.Chronic graft-versus-host disease: where do we go from here?
P2860
Q24235827-A1AAB57E-423A-4F16-8D43-44D6EF30C3D2Q24630836-28E04D71-091B-461C-94E6-07C45D81B64EQ26472072-EB083203-D6F3-4C9A-985A-F2E8280EC7BDQ27016541-3C916430-C89F-4D29-8F7C-9657ADF754A5Q28067102-51F96EDE-788D-49FA-9279-4E700ACEF3CFQ33360252-9F1DA87A-098C-406C-8442-3A4713ED0A2BQ33411822-B98D164F-1DAD-482D-88FD-E1A71E237F11Q33564445-54743B33-51BB-47DB-AB5B-7DAA1CA11E1CQ33642625-A2365ABE-B4EF-4094-A025-550E7DC0D8A5Q33699602-C16EB315-F36E-4666-A490-D3F80F5E96B1Q33747297-D49FD090-5110-4927-B093-51BB47D551E1Q33763908-43053439-9204-4371-9A87-100FE855DBF8Q33886907-E344454B-075B-4EA1-BE46-AB4B294E1F9CQ33917187-E8049CF4-4A4D-4D2D-A2C2-2EC4C765F3ACQ33941128-64280F27-AC00-4028-BB7D-4AC61F3297ADQ33949546-60A78D14-26AA-4AAD-AF9C-44CD7091BC2DQ33964687-8E497B99-5E66-45C4-814D-BE16E21A8E92Q34111627-604A6120-83C2-45B9-9D6F-B3A8B5606265Q34233378-DDFA00A2-D5AF-49DE-81FC-EE8F64901B22Q34269481-F40C779A-C0E5-4D5B-898E-4CDB165ED501Q34288677-AA318BEC-1528-4029-8048-BA26CF5C1940Q34388640-6B78AB11-A738-4142-92B6-6AF2980B21F2Q34443622-750E1E9F-7BDC-461C-AC0B-40F0CF87AF9DQ34449575-4B2D6043-DC2B-49FB-9F7C-1F32A4584843Q34640239-5770C2CE-0E7D-4E7C-936D-9F6E6D7AA483Q34673038-A8D51A10-A65A-4716-B82B-DA34664A9EFEQ34734491-A5BD72B4-EF42-4F79-A278-57982433FEE8Q34806652-0C90E3E2-1044-4401-8E6E-71454A58E36FQ34859147-89AA272E-A55C-4CEE-AD14-DBADD9DB6785Q34973719-3FEC37BD-F670-4AD4-B431-2992DB9E6EE2Q35110765-4E43BB41-07F3-49B4-A520-B48E9F005919Q35285087-459EDF91-41AC-49F0-BE0B-CF0F75D1D135Q35478934-9F1F4E62-B4B2-42DA-B815-52DFFAE2CD42Q35483838-67E906D9-C6A4-4BD2-AE98-D663407CEA77Q35547257-34BF79C8-B371-43E1-94B9-920CD3E72616Q35561803-4237C464-229E-46C8-824D-849B6E20C458Q35571053-83EA138C-B009-4897-AFA4-45FDEF1B71D2Q35574536-B839A212-2728-4807-8361-0D89D13DB132Q35602633-9FBDA561-109E-46F8-BE6E-92CA4658AF74Q35638378-F9A15055-0071-4228-87DE-DCCC04332511
P2860
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Graft-versus-host disease afte ...... tic stem cell transplantation.
@ast
Graft-versus-host disease afte ...... tic stem cell transplantation.
@en
Graft-versus-host disease afte ...... tic stem cell transplantation.
@nl
type
label
Graft-versus-host disease afte ...... tic stem cell transplantation.
@ast
Graft-versus-host disease afte ...... tic stem cell transplantation.
@en
Graft-versus-host disease afte ...... tic stem cell transplantation.
@nl
prefLabel
Graft-versus-host disease afte ...... tic stem cell transplantation.
@ast
Graft-versus-host disease afte ...... tic stem cell transplantation.
@en
Graft-versus-host disease afte ...... tic stem cell transplantation.
@nl
P2093
P50
P1433
P1476
Graft-versus-host disease afte ...... tic stem cell transplantation.
@en
P2093
Mary E D Flowers
Michael B Maris
Paul J Martin
P304
P356
10.1182/BLOOD-2002-08-2628
P407
P577
2003-03-27T00:00:00Z